Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 5/20 | 0.40 |
| ▸ | HTR1D | P28221 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971528 | 1.00 | CA2 (0.42) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5722725 | 1.00 | CA2 (0.42) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL7222682 | 1.00 | CA2 (0.42) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL29462397 | 0.92 | CA2 (0.46) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1934942 | 0.82 | CA2 (0.38) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL30703411 | 0.81 | CHRM2 (0.42) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1567113 | 0.80 | HTR1A (0.45) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2395914 | 0.80 | CHRM2 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1451005 | 0.79 | STS (0.47) | CA2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL27918729 | 0.77 | CHRM2 (0.36) | CA2CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358239-B2 | Pyrrolidinyl, piperidinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-15 | — | — | US | disclosed |
| US-7273862-B2 | Aminoalkyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-25 | — | — | US | disclosed |
| US-20050159406-A1 | Pyrrolidinyl, piperidinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | DE BRUYN MARCEL F L (BE) | 2005-07-21 | — | — | US | disclosed |
| US-6900222-B1 | Pyrrolidinyl, piperdinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-31 | — | — | US | disclosed |
| US-20050096378-A1 | Aminoalkyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | VAN EMELEN KRISTOF (BE) | 2005-05-05 | — | — | US | disclosed |
| US-6864273-B1 | Aminoalkyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-08 | — | — | US | disclosed |
| EP-1187831-B1 | PYRROLIDINYL, PIPERIDINYL OR HOMOPIPERIDINYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2004-10-13 | — | — | EP | disclosed |
| EP-1187829-B1 | AMINOALKYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-12-10 | — | — | EP | disclosed |
| EP-1187829-A1 | AMINOALKYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES | Janssen Pharmaceutica N.V. (BE) | 2002-03-20 | — | — | EP | disclosed |
| EP-1187831-A1 | PYRROLIDINYL, PIPERIDINYL OR HOMOPIPERIDINYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000075137-A1 | PYRROLIDINYL, PIPERIDINYL OR HOMOPIPERIDINYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000075136-A1 | AMINOALKYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR BENZOPYRAN) DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159406-A1 | Pyrrolidinyl, piperidinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | HRH2, CBR1, CBR3 | CA2 115/4885CHRM2 39/4885CHRM4 331/4885 |
| US-20050096378-A1 | Aminoalkyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | CBR1, QSOX1, HRH2 | CA2 75/4885CHRM2 16/4885CHRM4 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.